MNMD logo

MNMD
Mind Medicine Inc - Ordinary Shares (Sub Voting)

25,968
Mkt Cap
$1.07B
Volume
5.33M
52W High
$14.43
52W Low
$4.70
PE Ratio
-9.70
MNMD Fundamentals
Price
$14.20
Prev Close
$13.39
Open
$13.46
50D MA
$11.09
Beta
1.71
Avg. Volume
1.47M
EPS (Annual)
-$1.54
P/B
5.81
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
MindMed to Report Q3 2025 Financial Results on November 6, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·3d ago
News Placeholder
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·3d ago
News Placeholder
MindMed Announces New Employee Inducement Grant
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·18d ago
News Placeholder
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Mind Medicine (MindMed) Inc. (MNMD) have performed compared to their sector so far this year.
Zacks·3mo ago
News Placeholder
All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy
Mind Medicine MindMed (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago
News Placeholder
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
Zacks·5mo ago
News Placeholder
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
Zacks·6mo ago
News Placeholder
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.
Stocktwits·8mo ago
News Placeholder
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·8mo ago

Latest MNMD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.